Meeting Abstract

Efficacy and Tolerability of Certolizumab pegol for the Treatment of rheumatoid Arthritis in clinical Practice in Germany: 3rd Interim Analysis of non-interventional Study "Fast"


Authors listBurmester, G.; Mueller-Ladner, U.; Nuesslein, H.; von Hinueber, U.; Edelmann, E.; Detert, J.; Hoehle, M.; Richter, C.; Klopsch, T.; Kumke, T.; Fricke, D.

Publication year2013

Pages100-100

JournalZeitschrift für Rheumatologie

Volume number72

ISSN0340-1855

eISSN1435-1250

PublisherSpringer



Citation Styles

Harvard Citation styleBurmester, G., Mueller-Ladner, U., Nuesslein, H., von Hinueber, U., Edelmann, E., Detert, J., et al. (2013) Efficacy and Tolerability of Certolizumab pegol for the Treatment of rheumatoid Arthritis in clinical Practice in Germany: 3rd Interim Analysis of non-interventional Study "Fast", Zeitschrift für Rheumatologie, 72, p. 100

APA Citation styleBurmester, G., Mueller-Ladner, U., Nuesslein, H., von Hinueber, U., Edelmann, E., Detert, J., Hoehle, M., Richter, C., Klopsch, T., Kumke, T., & Fricke, D. (2013). Efficacy and Tolerability of Certolizumab pegol for the Treatment of rheumatoid Arthritis in clinical Practice in Germany: 3rd Interim Analysis of non-interventional Study "Fast". Zeitschrift für Rheumatologie. 72, 100.


Last updated on 2025-02-04 at 02:17